Earnings ·
Pharming raises full-year revenue guidance to $380M-$390M after Q3 revenues hit $117.6M
PHARPharming Group N.V.
Pharming Group N.V. reports preliminary third-quarter 2026 total revenues of approximately US$117.6 million, a 21% increase from the prior-year period, driven by strong performance in RUCONEST and Joenja. The company has tightened its full-year 2026 revenue guidance to between US$380 million and US$390 million, up from the previous range of $375 million to $395 million, while lowering operating expense guidance. Full financial results will be reported on October 27, 2026. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for rare immune and genetic diseases.